These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 16626808

  • 1. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
    Quinn LP, Stean TO, Chapman H, Brown M, Vidgeon-Hart M, Upton N, Billinton A, Virley DJ.
    J Neurosci Methods; 2006 Sep 30; 156(1-2):218-27. PubMed ID: 16626808
    [Abstract] [Full Text] [Related]

  • 2. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
    Quinn LP, Perren MJ, Brackenborough KT, Woodhams PL, Vidgeon-Hart M, Chapman H, Pangalos MN, Upton N, Virley DJ.
    J Neurosci Methods; 2007 Aug 15; 164(1):43-9. PubMed ID: 17498809
    [Abstract] [Full Text] [Related]

  • 3. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Aug 15; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 4. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y.
    Neurosci Res; 2005 Mar 15; 51(3):265-74. PubMed ID: 15710490
    [Abstract] [Full Text] [Related]

  • 5. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A, Mura A, Hengerer B, Feldon J, Ferger B.
    Behav Brain Res; 2004 Oct 05; 154(2):375-83. PubMed ID: 15313025
    [Abstract] [Full Text] [Related]

  • 6. Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.
    Leng A, Yee BK, Feldon J, Ferger B.
    Behav Brain Res; 2004 Oct 05; 154(2):449-56. PubMed ID: 15313033
    [Abstract] [Full Text] [Related]

  • 7. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
    Hirst SJ, Ferger B.
    Synapse; 2008 Feb 05; 62(2):85-90. PubMed ID: 17992685
    [Abstract] [Full Text] [Related]

  • 8. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL.
    Neuropharmacology; 2006 Jul 05; 51(1):112-20. PubMed ID: 16678218
    [Abstract] [Full Text] [Related]

  • 9. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S, Nakano I, Nagatsu T, Sawada M.
    J Neurosci Res; 2007 Jun 05; 85(8):1752-61. PubMed ID: 17469135
    [Abstract] [Full Text] [Related]

  • 10. [The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome].
    Korshunov AM, Voronina TA, Churiukanov VV, Iakhno NN.
    Eksp Klin Farmakol; 1995 Jun 05; 58(6):7-9. PubMed ID: 8704620
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A.
    Exp Neurol; 2008 Mar 05; 210(1):182-93. PubMed ID: 18053987
    [Abstract] [Full Text] [Related]

  • 12. Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
    Li X, Matsumoto K, Murakami Y, Tezuka Y, Wu Y, Kadota S.
    Pharmacol Biochem Behav; 2005 Oct 05; 82(2):345-52. PubMed ID: 16214209
    [Abstract] [Full Text] [Related]

  • 13. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Yarkov AV, Hanger D, Reploge M, Joyce JN.
    Pharmacol Biochem Behav; 2003 Dec 05; 76(3-4):551-62. PubMed ID: 14643855
    [Abstract] [Full Text] [Related]

  • 14. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
    Hong Z, Wang G, Gu J, Pan J, Bai L, Zhang S, Chen SD.
    Eur J Neurosci; 2007 Sep 05; 26(6):1500-8. PubMed ID: 17714494
    [Abstract] [Full Text] [Related]

  • 15. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
    Luchtman DW, Shao D, Song C.
    Physiol Behav; 2009 Aug 04; 98(1-2):130-8. PubMed ID: 19410592
    [Abstract] [Full Text] [Related]

  • 16. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
    Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K.
    J Neurochem; 2006 May 04; 97(4):1126-35. PubMed ID: 16686692
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY, Park HJ, Ahn YH, Lee PH.
    J Neurochem; 2009 Nov 04; 111(4):1042-50. PubMed ID: 19765187
    [Abstract] [Full Text] [Related]

  • 18. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
    Grealish S, Mattsson B, Draxler P, Björklund A.
    Eur J Neurosci; 2010 Jun 04; 31(12):2266-78. PubMed ID: 20529122
    [Abstract] [Full Text] [Related]

  • 19. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
    Stephenson D, Ramirez A, Long J, Barrezueta N, Hajos-Korcsok E, Matherne C, Gallagher D, Ryan A, Ochoa R, Menniti F, Yan J.
    J Neurosci Methods; 2007 Jan 30; 159(2):291-9. PubMed ID: 16949674
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW, Bradbury KA, Schneider JS.
    Eur J Neurosci; 2006 Dec 30; 24(11):3174-82. PubMed ID: 17156378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.